Literature DB >> 17160544

Lymphoproliferative disorder presenting as a tumor of the renal allograft.

S M Moudouni1, M Tligui, J D Doublet, F Haab, B Gattegno, Ph Thibault.   

Abstract

Post-transplant lymphoproliferative diseases (PTLDs) constitute a group of potentially life-threatening complications in solid organ transplantation, occurring in 1-2% of kidney transplant recipients. The absolute number of cases occurring at each transplant center remains small, making it difficult to assess incidence, prognosis, and treatment. We report a case of post-transplant lymphoproliferative disorder that developed in the allograft renal parenchyma 2 years after renal transplantation. This case implies that partial nephrectomy may be a safe and effective treatment protocol for renal lymphoma in allograft kidneys.

Entities:  

Mesh:

Year:  2006        PMID: 17160544     DOI: 10.1007/s11255-006-0067-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  9 in total

1.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.

Authors:  L J Swinnen; M R Costanzo-Nordin; S G Fisher; E J O'Sullivan; M R Johnson; A L Heroux; G J Dizikes; R Pifarre; R I Fisher
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

Review 2.  Incidence and consequences of post-transplantation lymphoproliferative disorders.

Authors:  S Boubenider; C Hiesse; C Goupy; F Kriaa; S Marchand; B Charpentier
Journal:  J Nephrol       Date:  1997 May-Jun       Impact factor: 3.902

Review 3.  Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; R L Simmons
Journal:  Transplantation       Date:  1985-05       Impact factor: 4.939

Review 4.  Mechanisms of action of mycophenolic acid.

Authors:  A C Allison; W J Kowalski; C D Muller; E M Eugui
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

5.  Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation.

Authors:  C E Kew; R Lopez-Ben; J K Smith; M L Robbin; W J Cook; R S Gaston; M H Deierhoi; B A Julian
Journal:  Transplantation       Date:  2000-03-15       Impact factor: 4.939

6.  Posttransplantation lymphoproliferative disorder in a renal allograft recipient.

Authors:  S Goral; R Felgar; S Shappell
Journal:  Am J Kidney Dis       Date:  1997-08       Impact factor: 8.860

Review 7.  Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression.

Authors:  B Melosky; M Karim; A Chui; M McBride; E C Cameron; C K Yeung; D Landsberg; C Shackleton; P A Keown
Journal:  J Am Soc Nephrol       Date:  1992-06       Impact factor: 10.121

8.  Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy.

Authors:  D W Hanto; K J Gajl-Peczalska; G Frizzera; D C Arthur; H H Balfour; K McClain; R L Simmons; J S Najarian
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

9.  Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.

Authors:  R C Walker; C V Paya; W F Marshall; J G Strickler; R H Wiesner; J A Velosa; T M Habermann; R C Daly; C G McGregor
Journal:  J Heart Lung Transplant       Date:  1995 Mar-Apr       Impact factor: 10.247

  9 in total
  1 in total

1.  Post-transplant lymphoproliferative disorder presenting as a tumor adjacent to the renal allograft: A case report and review of the literature.

Authors:  Chen Gao; Longkai Peng; Fenghua Peng; Ting Tuo; Daiqiang Li
Journal:  Oncol Lett       Date:  2014-10-02       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.